MAPT and Alzheimer disease: Newly tested MTDLs affect various pathways involved in the development of AD, mainly focusing on reducing cholinergic depletion, glutamate toxicity, Aβ aggregation, tau hyperphosphorylation, and oxidative stress [342,343,344,345,346].